Nice results for experimental blood pressure drug from Gilead – Gilead Sciences Inc said on Thursday its experimental drug to treat patients whose high blood pressure is not controlled by other medicines met both the primary goals of a late-stage study, sending its shares 5 percent higher. “In this study, more than half of the patients treated with darusentan achieved goal blood pressure, as compared to approximately one quarter of patients receiving placebo,” Gilead’s research chief Norbert Bischofberger said in a statement.
Pfizer launching Detrol replacement (Toviaz). The most interesting part of the article is what it has to say about less dependence on sales reps for promotion. As the clock ticks down on patents for Pfizer’s $1.2 billion blockbuster drug Detrol, the drug giant is launching a new one to take its place: overactive-bladder remedy Toviaz. The idea is to educate patients while freeing up physicians’ time — and reducing the need for a large sales force. Jim Maffezzoli, senior director-marketing in Pfizer’s new primary-care unit, which is marketing the drug, said the sales force will be “significantly smaller” than before and will be retrained to become more of a partner to physicians and understand their needs.
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff